Evaluation of Pregnancy Outcome with Usage of Drug-free In-vitro Activation of Follicles Ovary
Evaluation of Pregnancy Outcome in Poor Responder Patients in IVF Cycle with Usage of Drug-free In-vitro Activation of Follicles Ovary
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Malihe Mahmoudinia
- Phone Number: _+98513338801
- Email: Mahmoudiniam@mums.ac.ir
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Women under 35 years of age who have one of the following characteristics:
Or poor response to gonadotropins in a previous IVF cycle (fewer than 3 oocytes in a previous IVF cycle)
Or ovarian reserve test AMH less than 1.1
Exclusion Criteria:
- Unwillingness to continue working with the researcher during the procedure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Experimental: Drug -free invitro activation of ovary in women
|
Drug free invitro activation Ovary
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of embryos
Time Frame: Within 3 weeks after ovarian stimulation
|
Within 3 weeks after ovarian stimulation
|
|
|
The number of oocytes obtained at oocyte pick-up (OPU)
Time Frame: Within 3 weeks after ovarian stimulation
|
Within 3 weeks after ovarian stimulation
|
|
|
Quality of embryos at the end of IVF treatment
Time Frame: Within 3 weeks after ovarian stimulation
|
A grade embryo was defined to have four blastomeres on the second day and seven or eight blastomeres on the third day with equal size and <20% fragmentation (high quality).
Blastocyst embryos were assessed according to Gardner's criteria.
|
Within 3 weeks after ovarian stimulation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Implantation rate
Time Frame: 4-8 weeks after transfer
|
4-8 weeks after transfer
|
|
Clinical pregnancy rate
Time Frame: one month after transfer
|
one month after transfer
|
|
Miscarriage rate
Time Frame: 20 weeks after transfer
|
20 weeks after transfer
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IR.MUMS.IRH.REC.1403.127
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.